• Cancer is second deadly disease after cardiovascular diseases.
Introduction
Cancer is a multifaceted disease that represents one of the leading causes of mortality in developed countries. Worldwide, one in eight deaths is due to cancer and it is the second most common cause of death in the US, exceeded only by heart disease, accounting for nearly one of every four deaths (http://www.cancer.org). The World Health Organization (WHO) projects that without immediate action, the global number of deaths from cancer will increase by nearly 80% by 2030, with most occurring in low-and middle-income countries.
External factors (such as tobacco, infectious organisms, chemicals, and radiation) and internal factors (inherited mutations, hormones, immune conditions, and mutations that occur from metabolism) are mostly responsible for cancer. These causal factors may act together or in sequence to initiate or promote the development of cancer (http://www.state.nj.us /health/cancer/causes.shtml).
While tremendous efforts have been made over the past decades to improve the available therapeutic options, and a large number of potent chemotherapeutic anticancer agents have been identified and successfully used in clinical practice, cancer still remains a major cause of disease and death in most countries. New therapeutic options to treat cancer are a high priority for most of the pharmaceutical companies and independent research organisations worldwide. Considerable research activity is devoted to the discovery of more potent treatments, while minimising their toxic side effects. However, most anticancer agents display a narrow therapeutic window due to their lack of selectivity against cancer cells (Shengquan et al., 2013; Kratz et al., 2008) . The ultimate goal of cancer chemotherapy is the development of selective drugs that can kill malignant tumor cells or render them benign without affecting normal cells. Thus, there is an overwhelming need to develop new chemopreventative agents that are both effective and safe (Sporn and Liby, 2005) . One practical approach to this problem is the use of terrestrial plants as a platform for drug development.
Plants have played a dominant role in the development of sophisticated traditional medicine systems. The WHO estimates that approximately 80 % of the population in some Asian and African countries depend on traditional medicine for primary health care. Plant products, however, also play an important secondary role in the health care sectors of developed countries, with 70% to 80% of populations of developed countries having used some form of alternative or complementary medicine (e.g. acupuncture). Herbal treatments are the most popular form of traditional medicine, and are highly lucrative in the international marketplace. The global market for herbal products is expected to reach $5 Trillion by 2050 (Anand and Neetu, 2011) .
Plants products have a long history of use in the treatment of cancer. Hartwell in his review of plants used against cancer lists more than 3000 plant species (Kaur et al., 2011) . Plant based drug discovery has resulted in the development of many anticancer drugs currently in clinical use. Besides this it also provides a platform for design of novel and safe drugs through proper understanding of the complex synergistic interaction of various constituents of anticancer herbs (Larkin, 1983; Saxe, 1987) There are four major structural classifications of plant-derived anticancerous compounds, namely vinca alkaloids, epipodophyllotoxin lignans, taxane diterpenoids and camptothecin quinoline alkaloid derivatives. These substances embrace some of the most exciting new chemotherapeutic agents currently available for use in a clinical setting.
Vinca alkaloids and its semisynthetic analogues
The era of using plant material as anticancer agents started with the isolation of two alkaloids vinblastine (1) and vincristine (2) from the Madagascar periwinkle, Catharanthus roseus G. Don (Apocynaceae) (Verma and Singh, 2010) . These two drugs have been used in clinical oncology for almost 50 years and work by blocking the polymerization of tubulin molecules into microtubules, preventing the formation of the mitotic spindle which result in metaphase arrest and apoptosis (Jordan et al, 1991) . A series of semisynthetic analogues of these two important drug molecules have been developed. The first semisynthetic vinca alkaloid to enter into human clinical trials was vindesine (eldisine, 3) in which the C(23) acetyl group in vinblastine was changed to an amido group (Jordan and Wilson, 2004) . Vindesine is primarily used to treat acute lymphocytic leukemia (ALL). Less frequently, it is prescribed for use in breast cancer, blast crisis of chronic myelocytic leukemia (CML), colorectal cancer, non-small cell lung cancer (NSCLC), and renal cell cancer (kidney cancer). Vindesine is used in countries such as Britain, South Africa, and several European countries, but it is not approved by the FDA, and is thus not commercially available in the U.S. Eli Lilly discontinued Eldisine in Canada in 1998 to make way for newer, more effective vinca alkaloid drugs (http://www.encyclopedia.com/topic/Vindesine.aspx).
Vinorelbine (Navelbine, 4), is another semisynthetic derivative of vinblastine in which the bridge linking the indole ring to the piperidine nitrogen has been shortened by one carbon and water has been eliminated from the piperidine ring. The drug was approved in France in 1989 under the brand name Navelbine for the treatment of NSCLC (http://www.pierrefabre.com/en). It gained approval to treat metastatic breast cancer (MBC) in 1991.
Vinorelbine received approval by the FDA in December 1994 sponsored by Burroughs Wellcome Company. Pierre Fabre Group now markets Navelbine in the U.S (Smith, 1995;  http://www.drugs.com/pro/vinorelbine.html). 
Taxol and its semisynthetic analogues
The discovery of paclitaxel (Taxol, 9) from the bark of the Pacific Yew, Taxus brevifolia Nutt (Taxaceae) provides further evidence for the success of natural product drug discovery.
No naturally occurring anticancer agent has made a bigger impact on cancer treatment than paclitaxel. Paclitaxel was the first compound discovered to promote microtubule formation and has been used in the treatment of several types of cancers particularly ovarian and breast cancers as well as NSCLC (Kinghorn and Seo, 1996) . A number of its semisynthetic TPI-287 (Tapestry Pharmaceuticals, 16) is reported to be undergoing phase I/II study in combination with temozolomide for the treatment of melanoma (NCT01067066), phase I/II study for safety and efficacy study in the treatment of neuroblastoma and medulla blastoma (NCT01483820), a randomised efficacy study to treat primary refractory or early relapsed neuroblastoma (NCT01505608) and is also undergoing phase II studies to treat breast cancer 
Podophyllotoxin and its semisynthetic analogues
Podophyllotoxin (22), obtained from Podophyllum peltatum, is another important anti-cancer compound (Imbert, 1998) . Some 30 years after its discovery, it was demonstrated that this compound binds reversibly to tubulin (Wilson et al., 1975 ) and therefore had potential as an Co-polymers have also been used as prodrugs of CPTs. MAG-CPT is a copolymer linked to CPT through a glycylaminohexanoyl-glycyl spacer which was developed by Pharmacia and
Camptothecin and its semisynthetic analogues
Upjohn in an attempt to overcome problems associated with the delivery of CPT.
Unfortunately because of toxicity issues, its development was discontinued after phase I 
Combretastatin and its analogues
Combretastatins have been isolated from the bark of the South African tree Combretum caffrum Kuntze (Combretaceae). Combretastatin A4 (40) Besides these, a large number of other anticancer agents isolated from plants are listed in Table 1 . 
